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Letters to the EditorInﬂiximab as rescue therapy in paediatric autoimmune hepatitisTo the Editor:
We read with interest the report by Weiler-Normann et al. [1]
regarding use of inﬂiximab (IFX) to obtain remission in adults
with difﬁcult-to-treat autoimmune hepatitis (AIH). We report
our paediatric experience with IFX for a patient with autoim-
mune hepatitis type 1, recalcitrant to standard medical treat-
ment, achieving sustained biochemical response, steroid
weaning, and prolonged deferral from liver transplantation.
Our female patient presented at 10 years of age with hepatic
failure, INR 2.5, albumin 25 g/L, bilirubin 212 lM/L (normal <20).
Hepatobiliary sonography demonstrated macronodular hepatic
changes and splenomegaly consistent with chronic liver disease.
Anti-smooth muscle antibody T fraction and IgG levels were ele-
vated at 1:160 and 24 mg/L, respectively. P-ANCA was negative.
Liver biopsy demonstrated massive hepatic necrosis, interface
hepatitis characterised by plasma cell inﬁltrate with no evidence
of cholangitis and no excess of stainable copper or rhodanine.
Extensive investigations for other causes of chronic liver disease
were negative and a diagnosis of type 1 AIH was conﬁrmed. Bio-
chemical response to prednisolone (1 mg/kg/day), followed by
azathioprine (up to 2 mg/kg/day) was slow and incomplete, lead-
ing, 7 months later, to a second biochemical relapse despite good
compliance (6-TG level 440 pmol/8  108 RBC, 6MMP levels
1200 pmol/8  108 RBC) and continuing prednisolone (10 mg/
day). MRCP showed no evidence of sclerosing cholangitis overlap.
A diagnosis of inﬂammatory bowel disease was not supported by
the absence of stooling abnormalities on history and stool exami-
nation although not formally excluded. Mycophenolate mofetil
(40 mg/kg/day) replaced azathioprine for three months with the
prednisolone dosage gradually weaned. Liver function tests failed
to respond then deteriorated, prompting high dose intravenous
methylprednisolone (2 mg/kg/day) with poor response. Then
tacrolimus (0.2 mg/kg/day) was combined with oral prednisolone
(40 mg/day) for one month with no biochemical improvement.
Severe steroid related side effects developed including Cushing’s
syndrome and hyperglycemia requiring insulin. Tacrolimus was
discontinued, azathioprine recommenced and our patient was
evaluated for liver transplantation. Based on the case report of
Weiler-Normann [2], a single dose 5 mg/kg (200 mg) IFX was
approved (drug and therapeutics ethics committee) for off-label
use by our institution. Following IFX, she experienced biochemical
and clinical improvement within 3 weeks, permitting successful
weaning of steroids from 40 mg daily to 2.5 mg on alternate days
by 8 weeks. The response was sustained for 4 months, allowing
reversal of steroid related side effects and temporary delisting
for liver transplantation. Subsequent biochemical relapse led to
permission for 3 further doses of IFX (5 mg/kg) at 4 weekly inter-
vals, although a re-increase in prednisolone dosage was avoided.
Infusions were well tolerated, with no side effects or adverse
events. A sustained biochemical response was achieved by
12 weeks, permitting further deferral of transplantation and dra-
matically improving quality of life. Ninemonths after her last dose
of IFX, our patient was successfully transplanted. Histology of the
explant liver showed no evidence to support a co-existing diagno-
sis of autoimmune sclerosing cholangitis. From her ﬁrst IFX until
transplant 19 months later, prednisolone was not increased above
2.5 mg daily (Fig. 1).
TNF-a antagonists are used successfully in the treatment of
several autoimmune conditions [3,4]. To our knowledge, the efﬁ-
cacy and safety of IFX in paediatric AIH remain unknown. Primary
concerns limiting its use relate to risks of infusion-related reac-
tions, serious infection, and autoimmune reactions including a
lupus-like syndrome as well as a recently reported hepatotoxicity
resembling AIH [5–7]. We report a paediatric case of AIH, unre-
sponsive to standard immunosuppressive therapies, with a sus-
tained response to IFX, permitting reversal of high dose
steroids, improving quality of life, and achieving a 19-month
deferral from liver transplantation.
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Flow cytometry makes all the difference
To the Editor:
We read with interest the reported association between natural
killer (NK) cell phenotype and treatment outcome in chronic
HCV infection [1]. There is growing evidence that NK cell
function and phenotype, in particular NKp46 expression, are
associated with liver inﬂammation, treatment outcome, and
may even impinge upon the ability to mount a robust CD4+
T-cell response during the successful IFN-a based treatment
of HCV [2–6]. However, this remains a complex ﬁeld with
often apparently conﬂicting reports within the literature.
Methodological variations are often cited as a cause of these
discrepancies.
The paper by Oliviero et al. reporting a novel association
between proportions of peripheral blood CD56dimCD16neg NK
cells and sustained virological response (SVR) is potentially extre-
mely exciting. CD16 is a weak FccRIII activating receptor that is
usually described as present on CD56dim, but not CD56bright, NK
cells in the resting state. CD16 is downregulated on cells that
have recently degranulated [7] and both we and the Mondelli
group have recently reported lower expression of CD16 on intra-
hepatic NK cells compared to peripheral blood [5,6]. Oliviero et al.
report that CD16neg cells make up a mean of 25% of CD56dim NK
cells in HCV patients and higher proportions of these cells are
associated with SVR. Furthermore, the proportion of this subset
increases after initiation of IFNa treatment. They speculate that
these NK cells may have come into contact with infected hepato-
cytes and degranulated, resulting in CD16 downregulation before
returning to the peripheral blood.
These ﬁndings are not compatible with those of other reports.
Using data from a previously described cohort of HCV patients
[6], we found 8% of NK cells are CD56dimCD16neg NK cells (range
3–17%), thus markedly lower than reported by Oliviero and col-
leagues. We found no association between the proportion of
CD56dim/bright or CD56dimCD16neg NK cells and treatment out-
come (Fig. 1A and B). What might be the basis for these contrast-
ing ﬁndings? We believe a key difference between our
methodologies is our inclusion of a cell marker to exclude dead
cells (Aqua Live/Dead, Invitrogen, Paisley, UK). The process of
storing cells in DSMO-based freezing media and liquid nitrogen
is potentially extremely toxic and it is well known that cell death
can result in non-speciﬁc and erratic antibody-binding. We found
that without a Live/Dead gate, there is an increase in the propor-
tion of cells appearing as CD56dimCD16neg. Indeed, retrospective
gating for dead cells revealed the majority (mean = 94.9%) were
within the CD56dimCD16neg gate and formed on average 20%
(range 5.2–52.1%) of events in this gate (p <0.0001, Fig. 1C–E).
Therefore, it is possible that dead cell contamination compro-
mises the data and conclusions presented in the study performed
by Oliviero and colleagues.
The role of NK cells in HCV is currently of great interest. The
majority of data from peripheral blood and intrahepatic NK cells
are likely to be analysed by ﬂow cytometry. We would therefore
like to recommend the following points for consideration. Single
cells should be selected and dead cells excluded from analyses.
Representative FACS plots should demonstrate the lymphocyte
gate, alive/dead staining, doublets, and NK gating. CD14+ and
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Fig. 1. Course of liver enzymes fromMay 2009 until June 2012. Alanine aminotransaminase (ALT) and aspartate aminotransaminase (AST) values are depicted (IU/L). The
light blue shade areas denoted IFX reﬂect the time of inﬂiximab treatment. Additional immunosuppressive therapy is depicted at the bottom: the large arrow represents a
weaning course or low dose prednisolone, HD represents high dose steroid, the AZA arrow azathioprine, the MF arrow mycophenolate mofetil, and the TAC arrow
tacrolimus.
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